SaraSmallMD Profile
SaraSmallMD

@SaraSmallMD1

Followers
172
Following
211
Media
3
Statuses
19

Assistant professor at Fox Chase Cancer Center. Physician Scientist. Leukemia researcher.

Chicago, IL
Joined April 2020
Don't wanna be here? Send us removal request.
@SaraSmallMD1
SaraSmallMD
2 years
Really going to miss Chicago and these views!
1
0
23
@FDAOncology
FDA Oncology
2 years
A great group of fellows – we were thrilled to welcome them to the White Oak Campus for #ProjectODACOdyssey! Thank you to @AACR for your collaboration! #OCEProjectSocrates @drjennifergao @realrickpazdur Next application period opens 6/1. Bookmark this🔽 https://t.co/TrMIsCDQWq
2
9
27
@SaraSmallMD1
SaraSmallMD
3 years
Made it to EHA! #EHA2022
6
2
54
@SaraSmallMD1
SaraSmallMD
4 years
Wordle 236 3/6 🟨⬛🟨🟨⬛ ⬛🟨⬛⬛🟩 🟩🟩🟩🟩🟩
0
0
3
@SaraSmallMD1
SaraSmallMD
4 years
Wordle 234 2/6 ⬛🟩🟩⬛🟩 🟩🟩🟩🟩🟩
1
0
3
@SaraSmallMD1
SaraSmallMD
4 years
Wordle 227 3/6 🟨🟨⬜⬜⬜ ⬜🟩🟩🟩🟨 🟩🟩🟩🟩🟩beginner’s luck!
2
0
4
@romeerizwan
Rizwan Romee
4 years
Cell-free DNA profiling informs all major complications of hematopoietic cell transplantation | PNAS
Tweet card summary image
pnas.org
Allogeneic hematopoietic cell transplantation (HCT) provides effective treatment for hematologic malignancies and immune disorders. Monitoring of p...
3
16
77
@scisignal
Science Signaling
4 years
Don’t miss this week’s new issue of Science Signaling! A “master” cytokine coordinates how cells respond to DNA damage, how naïve T cells survive in the periphery, interrogating synaptic transmission in the mouse brain, and more! https://t.co/dDCfUNe6GT
0
3
7
@scisignal
Science Signaling
4 years
The Brown lab discovers that IL-19 acts as a “master” #cytokine that triggers proinflammatory cytokine secretion in cells responding to DNA damage from ionizing radiation, chemotherapy, and other insults. @PennCancer #Inflammation https://t.co/KKawpqMSXM
0
1
4
@SaraSmallMD1
SaraSmallMD
4 years
So much purple pride at #ASH21!
0
7
58
@SaraSmallMD1
SaraSmallMD
4 years
On my way to #ASH21!!
0
0
7
@NatRevClinOncol
NatureRevClinOncol
5 years
Changes in BCL-2 family members in response to ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in pts with CLL and provides a biological rationale for combination of these two agents: https://t.co/urFQbn1EJ5 #leusm #hemeonc
0
8
10
@SaraSmallMD1
SaraSmallMD
6 years
Acalabrutinib COVID-19 Trial Launching https://t.co/SZ05jTbLWc via @onclive
0
0
2